Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27803030 | 0.87 | NAMPT (0.53) | NAMPTMAPTMEN1KMT2APKM | |
| SCHEMBL12549987 | 0.83 | KEAP1 (0.58) | LMNASMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL12077597 | 0.82 | NAMPT (0.71) | NAMPTMEN1KMT2A | |
| SCHEMBL750261 | 0.80 | MEN1 (0.58) | NAMPTLMNASMN1; SMN2CYP2C19MAPT | |
| SCHEMBL18725052 | 0.78 | KEAP1 (0.71) | NAMPTLMNASMN1; SMN2CYP2C19MAPT | |
| SCHEMBL18725325 | 0.78 | L3MBTL1 (0.53) | LMNAMAPTMEN1KMT2APKM | |
| SCHEMBL28120961 | 0.77 | PTGER2 (0.57) | NAMPTPTGER2PTGER4MAPTMEN1 | |
| SCHEMBL15651151 | 0.77 | CA12 (0.59) | NAMPTLMNASMN1; SMN2CYP2C19MAPT | |
| SCHEMBL533757 | 0.77 | LMNA (0.56) | NAMPTLMNASMN1; SMN2CYP2C19MAPT | |
| SCHEMBL119971 | 0.77 | MAPT (0.71) | NAMPTMAPTMEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106458904-B | N-substituted sulfonamide compound and process for producing the same | 宇部兴产株式会社 | 2021-12-03 | — | — | CN | disclosed |
| EP-3156396-B1 | METHOD FOR PRODUCING A N-SUBSTITUTED SULFONAMIDE COMPOUND | UBE INDUSTRIES (JP) | 2021-07-21 | — | — | EP | disclosed |
| CN-106458903-B | Method for producing heteroaromatic sulfonamide compound | 宇部兴产株式会社 | 2021-02-05 | — | — | CN | disclosed |
| US-10774072-B2 | Crystal of N-substituted sulfonamide compound | UBE INDUSTRIES, LTD. (JP) | 2020-09-15 | — | — | US | disclosed |
| US-10428046-B2 | N-substituted sulfonamide compound and method for producing same | UBE INDUSTRIES, LTD. (JP) | 2019-10-01 | — | — | US | disclosed |
| EP-3156395-B1 | METHOD FOR PRODUCING HETEROAROMATIC SULFONAMIDE COMPOUND | UBE INDUSTRIES (JP) | 2019-01-09 | — | — | EP | disclosed |
| EP-3156395-B1 | METHOD FOR PRODUCING HETEROAROMATIC SULFONAMIDE COMPOUND | UBE INDUSTRIES (JP) | 2019-01-09 | — | — | EP | disclosed |
| US-20170121288-A1 | METHOD FOR PRODUCING HETEROAROMATIC SULFONAMIDE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2017-05-04 | — | — | US | disclosed |
| US-20170121288-A1 | METHOD FOR PRODUCING HETEROAROMATIC SULFONAMIDE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2017-05-04 | — | — | US | disclosed |
| US-20170121288-A1 | METHOD FOR PRODUCING HETEROAROMATIC SULFONAMIDE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3156395-A1 | METHOD FOR PRODUCING HETEROAROMATIC SULFONAMIDE COMPOUND | UBE Industries, Ltd. (JP) | 2017-04-19 | — | — | EP | disclosed |
| CN-106458904-A | N-substituted sulfonamide compound and method for producing same | 宇部兴产株式会社 | 2017-02-22 | — | — | CN | disclosed |
| CN-106458903-A | Method for producing heteroaromatic sulfonamide compound | 宇部兴产株式会社 | 2017-02-22 | — | — | CN | disclosed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774072-B2 | Crystal of N-substituted sulfonamide compound | STS, SLC10A6, CA3 | NAMPT 1765/4885PTGER2 2772/4885PTGER4 2952/4885 |
| US-10428046-B2 | N-substituted sulfonamide compound and method for producing same | STS, CA7, CA4 | NAMPT 2197/4885PTGER2 2352/4885PTGER4 2533/4885 |
| US-20170121288-A1 | METHOD FOR PRODUCING HETEROAROMATIC SULFONAMIDE COMPOUND | PFAS, SULT2A1, ARSA | NAMPT 4338/4885PTGER2 1726/4885PTGER4 2554/4885 |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | NAMPT 2339/4885PTGER2 1/4885PTGER4 17/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | NAMPT 2422/4885PTGER2 1/4885PTGER4 17/4885 |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | NAMPT 3499/4885PTGER2 24/4885PTGER4 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.